References
-
1) MARK2 enhances cisplatin resistance via PI3K/AKT/NF-κB signaling pathway in osteosarcoma cells.
Product: MARK2 Antibody (#DF3329)Year: 2020Journal: Am J Transl ResImpactFactor: 1.7PMID: 32509178 -
2) 7-Difluoromethoxy-5, 4′-dimethoxy-genistein attenuates macrophages apoptosis to promote plaque stability via TIPE2/TLR4 axis in high fat diet-fed ApoE−/− mice.
Product: TNFAIP8L2 Antibody (#DF3326)Year: 2021Journal: INT IMMUNOPHARMACOLImpactFactor: 4.8DOI: 10.1016/j.intimp.2021.107477PMID: 33813367 -
3) Tumor necrosis factor α‑induced protein 8‑like 2 contributes to penehyclidine hydrochloride pretreatment against lipopolysaccharide‑induced acute lung injury in a mouse model.
Product: TNFAIP8L2 Antibody (#DF3326)Year: 2021Journal: MOL MED REPImpactFactor: 3.4DOI: 10.3892/mmr.2021.12390PMID: 34468006 -
4) Expression and regulation of tumor necrosis factor-α-induced protein-8-like 2 is associated with acute lung injury induced by myocardial ischemia reperfusion in diabetic rats.
Product: TNFAIP8L2 Antibody (#DF3326)Year: 2020Journal: MICROVASC RESImpactFactor: 2.9DOI: 10.1016/j.mvr.2020.104009PMID: 32333940 -
5) Olaquindox disrupts tight junction integrity and cytoskeleton architecture in mouse Sertoli cells.
Product: DOK7 Antibody (#DF3308)Year: 2017Journal: ONCOTARGETDOI: 10.18632/oncotarget.20289PMID: 29179463 -
6) Silencing of PFKFB3 protects podocytes against high glucose‑induced injury by inducing autophagy.
Product: PFKFB1/4 Antibody (#DF3307)Year: 2021Journal: MOL MED REPImpactFactor: 3.4DOI: 10.3892/mmr.2021.12405PMID: 34490476 -
7) A Bone Morphogenetic Protein Signaling Inhibitor, LDN193189, Converts Ischemia-Induced Multipotent Stem Cells into Neural Stem/Progenitor Cell-Like Cells.
Product: Smad1/5/9 Antibody (#DF3300)Year: 2022Journal: Stem Cells DevImpactFactor: 2.5DOI: 10.1089/scd.2022.0139PMID: 36053672 -
8) SUMOylation modification of FTO facilitates oxidative damage response of arsenic by IGF2BP3 in an m6A-dependent manner.
Product: WTAP Antibody (#DF3282)Year: 2024Journal: J Hazard MaterImpactFactor: 12.2DOI: 10.1016/j.jhazmat.2024.134440PMID: 38723480 -
9) Comprehensive Analysis of the Transcriptome-Wide m6A Methylation Modification Difference in Liver Fibrosis Mice by High-Throughput m6A Sequencing.
Product: WTAP Antibody (#DF3282)Year: 2021Journal: FRONT CELL DEV BIOLImpactFactor: 4.6DOI: 10.3389/fcell.2021.767051PMID: 34869362 -
10) Sharp Downregulation of Hub Genes Associated With the Pathogenesis of Breast Cancer From Ductal Carcinoma In Situ to Invasive Ductal Carcinoma.
Product: MELK Antibody (#DF3278)Year: 2021Journal: FRONT ONCOLImpactFactor: 3.5DOI: 10.3389/fonc.2021.634569PMID: 34094915 -
11) MicroRNA-221-3p inhibits the inflammatory response of keratinocytes by regulating the DYRK1A/STAT3 signaling pathway to promote wound healing in diabetes.
Product: DYR1A Antibody (#DF3270)Year: 2024Journal: Commun BiolImpactFactor: 5.9DOI: 10.1038/s42003-024-05986-0PMID: 38461326 -
12) Network pharmacology- and cell-based assessments identify the FAK/Src pathway as a molecular target for the antimetastatic effect of momordin Ic against cholangiocarcinoma.
Product: FOXC1/2 Antibody (#DF3252)Year: 2024Journal: HeliyonImpactFactor: 4DOI: 10.1016/j.heliyon.2024.e32352PMID: 38961933 -
13) The expression of AGGF1, FOXC2, and E-cadherin in esophageal carcinoma and their clinical significance.
Product: FOXC1/2 Antibody (#DF3252)Year: 2020Journal: MEDICINEImpactFactor: 1.3DOI: 10.1097/MD.0000000000022173PMID: 32925786 -
14) Silencing FOXC1 inhibits growth and migration of human oral squamous cell carcinoma cells.
Product: FOXC1/2 Antibody (#DF3252)Year: 2018Journal: EXP THER MEDImpactFactor: 2.4DOI: 10.3892/etm.2018.6627PMID: 30233683 -
15) Dihydroartemisinin Attenuates Hypoxia-Induced Pulmonary Hypertension Through the ELAVL2/miR-503/PI3K/AKT Axis.
Product: ELAVL2 Antibody (#DF3251)Year: 2022Journal: J Cardiovasc PharmacolImpactFactor: 2.6DOI: 10.1097/FJC.0000000000001271PMID: 35512032